ストックスクリーナーアプリを入手
12.77
0.39%
-0.05
アフターアワーズ：
12.95
0.18
+1.41%
前日終値:
$12.82
開ける：
$12.82
24時間の取引高:
473.51K
Relative Volume:
0.80
時価総額：
$645.07M
収益：
$89.04M
当期純損益:
$-241.08M
株価収益率:
-2.4278
EPS:
-5.26
ネットキャッシュフロー:
$-194.72M
1週間 パフォーマンス:
-2.00%
1か月 パフォーマンス:
+32.33%
6か月 パフォーマンス:
+32.88%
1年 パフォーマンス:
+48.66%
1日の値動き範囲:
$12.61
$13.20
1週間の範囲:
$12.61
$13.93
52週間の値動き範囲:
$5.035
$13.93
Regenxbio Inc Stock (RGNX) Company Profile
RGNX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
RGNX
Regenxbio Inc
|
12.77 | 647.59M | 89.04M | -241.08M | -194.72M | -5.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Regenxbio Inc Stock (RGNX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-02-11 | ダウングレード | Goldman | Buy → Neutral |
| 2025-02-07 | 再開されました | Raymond James | Outperform |
| 2024-11-15 | 再開されました | Morgan Stanley | Overweight |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-06-07 | 開始されました | Goldman | Buy |
| 2024-03-11 | 開始されました | H.C. Wainwright | Buy |
| 2024-03-08 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-03-06 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-02-21 | 再開されました | Raymond James | Outperform |
| 2023-11-01 | 開始されました | Stifel | Buy |
| 2023-06-02 | 開始されました | Robert W. Baird | Outperform |
| 2022-06-23 | 開始されました | Berenberg | Buy |
| 2021-12-15 | 開始されました | Wedbush | Neutral |
| 2021-10-19 | 再開されました | Morgan Stanley | Overweight |
| 2021-01-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2020-12-16 | 開始されました | UBS | Buy |
| 2020-06-25 | 再開されました | BofA/Merrill | Buy |
| 2020-05-13 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2019-08-20 | アップグレード | SVB Leerink | Underperform → Mkt Perform |
| 2019-06-18 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-06-14 | 再開されました | Raymond James | Outperform |
| 2019-06-05 | 繰り返されました | Chardan Capital Markets | Buy |
| 2019-02-25 | アップグレード | Evercore ISI | In-line → Outperform |
| 2019-02-05 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-12-17 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-11-08 | 繰り返されました | BofA/Merrill | Neutral |
| 2018-08-08 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-23 | ダウングレード | BofA/Merrill | Buy → Neutral |
| 2018-07-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-05-09 | 繰り返されました | Barclays | Overweight |
| 2018-04-09 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-03-12 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2018-02-13 | 開始されました | Mizuho | Neutral |
| 2017-11-09 | 再開されました | Morgan Stanley | Overweight |
すべてを表示
Regenxbio Inc (RGNX) 最新ニュース
Visualizing REGENXBIO Inc. stock with heatmapsJuly 2025 Volume & Free Technical Confirmation Trade Alerts - newser.com
Analyzing recovery setups for REGENXBIO Inc. investorsMarket Performance Recap & Safe Entry Momentum Tips - newser.com
Can REGENXBIO Inc. (RB0) stock deliver strong annual returnsWeekly Trade Summary & Growth-Oriented Investment Plans - newser.com
Why REGENXBIO Inc. stock appeals to dividend seekersPortfolio Value Summary & Long-Term Growth Plans - newser.com
Is REGENXBIO Inc. stock overvalued by current metricsCEO Change & Weekly Watchlist for Hot Stocks - newser.com
Using economic indicators to assess REGENXBIO Inc. potentialWeekly Profit Report & Free Weekly Chart Analysis and Trade Guides - newser.com
AlphaQuest LLC Cuts Position in REGENXBIO Inc. $RGNX - MarketBeat
Will REGENXBIO Inc. (RB0) stock profit from fiscal stimulusPortfolio Update Report & Verified Momentum Stock Alerts - newser.com
Historical volatility pattern of REGENXBIO Inc. visualizedWeekly Trend Recap & Verified Short-Term Plans - newser.com
Is now a turning point for REGENXBIO Inc.Fed Meeting & Reliable Price Action Trade Plans - newser.com
REGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Why REGENXBIO Inc. stock is considered a top pickBreakout Watch & Technical Entry and Exit Tips - newser.com
Reversal indicators forming on REGENXBIO Inc. stockJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
RegenXBio (RGNX) Receives a Buy from H.C. Wainwright - The Globe and Mail
Is REGENXBIO Inc. stock undervalued vs historical averagesJuly 2025 Sentiment & Fast Moving Stock Watchlists - newser.com
Will REGENXBIO Inc. (RB0) stock outperform Dow Jones2025 EndofYear Setup & Precise Swing Trade Alerts - newser.com
Price momentum metrics for REGENXBIO Inc. explainedJuly 2025 Action & Daily Growth Stock Investment Tips - newser.com
Will REGENXBIO Inc. (RB0) stock sustain uptrend momentumInsider Selling & Technical Pattern Based Buy Signals - newser.com
What data driven models say about REGENXBIO Inc.’s futurePortfolio Risk Report & Risk Controlled Swing Trade Alerts - newser.com
Using Ichimoku Cloud for REGENXBIO Inc. technicals2025 Momentum Check & High Accuracy Swing Trade Signals - newser.com
REGENXBIO concludes subject enrolment in trial of RGX-202 - Clinical Trials Arena
Will REGENXBIO Inc. stock see PE expansionJuly 2025 Action & Risk Managed Trade Strategies - newser.com
Will REGENXBIO Inc. stock go up soonWeekly Investment Recap & Step-by-Step Swing Trade Plans - newser.com
REGENXBIO Inc. stock daily chart insightsBond Market & Capital Protection Trading Alerts - newser.com
Should I buy REGENXBIO Inc. (RB0) stock before earnings seasonRecession Risk & Verified High Yield Trade Plans - newser.com
Regenxbio (RGNX) Completes Enrollment for Duchenne Gene Therapy Trial - GuruFocus
REGENXBIO Inc. Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - MarketScreener
REGENXBIO completes pivotal trial enrollment for Duchenne gene therapy - Investing.com
Regenxbio announces completion of pivotal enrollment and initiates commercial production in Duchenne gene therapy program - MarketScreener
REGENXBIO completes pivotal trial enrollment for Duchenne gene therapy By Investing.com - Investing.com Nigeria
REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program - The AI Journal
REGENXBIO Announces Completion Of Pivotal Enrollment And Initiates Commercial Production In Duchenne Gene Therapy Program - TradingView
REGENXBIO (NASDAQ: RGNX) completes RGX-202 enrollment of 30, starts commercial supply - Stock Titan
Regenxbio Inc (RGNX) 財務データ
収益
当期純利益
現金流量
EPS
1.62%
0.21%
大文字化:
|
ボリューム (24 時間):